The Year 2026: How Synthetic Biology is Reshaping the Healthcare Industry and Ushering in a New Paradigm of Personalized Medicine
Editor
As of January 2026, synthetic biology has established itself as the most promising innovation in the healthcare industry. The global synthetic biology market grew from $32.8 billion in 2025 to $42 billion in 2026, marking a 28% increase, with the healthcare sector accounting for 67% or $28.1 billion of the total market. The personalized therapeutics segment, in particular, expanded to $12.6 billion, a 34% increase from the previous year. This rapid growth is largely attributed to the improvement in CRISPR-Cas9 technology, which has achieved an accuracy rate of 99.7%, and a 42% reduction in gene editing costs compared to 2024. Additionally, advancements in AI-driven protein design have reduced the drug development timeline from the traditional 10-15 years to 6-8 years, significantly enhancing the return on R&D investments for pharmaceutical companies.
Korea’s biotech industry occupies a unique position within this global trend. Samsung Biologics, headquartered in Seongnam, Gyeonggi Province, reported a 31% year-on-year increase in revenue, reaching 1.24 trillion won in Q4 2025. The company’s personalized antibody therapy, ‘SB-101’, demonstrated a 76% higher efficacy in Phase 2 clinical trials compared to standard treatments, utilizing technology that adjusts antibody structures in real-time based on individual genetic profiles. Similarly, Celltrion, based in Songdo, Incheon, is focusing on the development of biosimilars using synthetic biology. Their personalized insulin, ‘CT-P39′, set for release in Q1 2026, incorporates innovative technology that adjusts degradation rates according to patients’ metabolic patterns. Clinical trials showed that this product improved blood sugar control by 43% compared to existing insulin, while reducing side effects by 67%.
In the U.S. market, Moderna, headquartered in Cambridge, Massachusetts, is achieving remarkable results in developing personalized cancer vaccines using mRNA technology. Their ‘mRNA-4157’ can manufacture a customized vaccine targeting up to 34 neoantigens within 72 hours by analyzing a patient’s tumor genetic sequence. In Phase 2b trials completed in Q4 2025, the vaccine reduced melanoma recurrence rates by 44%, and the FDA is set to review its approval in March 2026. Gilead Sciences, based in Foster City, California, has adopted a personalized approach in the CAR-T cell therapy sector. Their ‘Yescarta-Plus’ enhances complete remission rates from 73% to 89% by determining the optimal gene editing combination through AI algorithms after harvesting a patient’s T-cells.
From a technological perspective, the core innovations in synthetic biology in 2026 lie in the commercialization of ‘multi-omics integrated analysis’ and ‘real-time biomarker monitoring’ technologies. Illumina, based in San Diego, California, has developed the ‘NovaSeq X Plus’, a next-generation sequencing device capable of completing whole-genome analysis in six hours at a cost of $600, a 38% reduction from 2024. These technological advancements enable the integrated analysis of genetic variations, protein expression patterns, and metabolomic profiles for each patient, facilitating the selection of optimal treatment methods. In cancer treatment, the development of multi-target therapies that consider tumor heterogeneity is gaining momentum. ‘Cocktail therapy’, which targets various cancer cell subtypes found in a patient’s tumor tissue simultaneously, is overcoming the limitations of traditional single-target therapies.
Changing Market Dynamics and Competitive Landscape
The rapid growth of the personalized therapeutics market is fundamentally altering the competitive landscape of the traditional pharmaceutical industry. As of 2026, the global personalized medicine market is valued at $784 billion, with therapeutics accounting for 45% or $352.8 billion. Notably, six of the top ten market share leaders are biotech startups established after 2020, indicating that the accessibility of synthetic biology technology has lowered entry barriers. Ginkgo Bioworks, headquartered in Boston, Massachusetts, provides synthetic biology technology to various biotech startups through its ‘biological manufacturing platform’, with 78 therapeutic candidates developed via the platform by 2025. The company reported $421 million in revenue in 2025, a 67% increase from the previous year, with 62% of revenue related to personalized therapeutics.
Korean companies are actively responding to these changes. Samsung Biologics announced in December 2025 the construction of a dedicated production facility for personalized therapeutics in Texas, USA, with a total investment of $3.2 billion. The facility is scheduled for completion in 2027 and will have the capacity to produce personalized therapeutics for up to 100,000 patients annually. Celltrion is also building an ‘AI-based biopharmaceutical development center’ in Songdo, Incheon, aiming for completion in the first half of 2026. This center will operate a system that analyzes patients’ omics data in real-time to propose optimal therapeutic combinations. Notably, the Korean government plans to introduce an expedited approval system for personalized therapeutics starting in 2026, potentially reducing clinical trial durations by up to 40% and accelerating market entry for treatments for rare diseases through conditional approvals.
In terms of competition, there is an increase in collaboration between established pharmaceutical companies and emerging biotech firms. Gilead Sciences acquired the UK-based personalized therapeutics developer ‘Precision Therapeutics’ for $1.4 billion in November 2025, securing AI-based drug design technology. Moderna has also entered a strategic partnership with Germany’s ‘BioNTech’ for the joint development of personalized cancer vaccines, with both companies planning to invest a total of $2.8 billion in joint R&D over the next five years. These collaborative models combine the capital and global distribution networks of large pharmaceutical companies with the innovative technologies of biotech firms, creating synergistic effects. In fact, therapeutics developed through such collaborations have shown a 34% higher clinical trial success rate compared to those developed independently.
Analyzing investment trends, venture capital investment in the global personalized therapeutics sector reached $18.7 billion in 2025, a 42% increase from the previous year. The highest growth rate was observed in the Asia region at 67%, with Korea attracting $2.3 billion, China $4.5 billion, and Japan $1.8 billion in investments. The investment pattern shows a shift from early-stage (Series A-B) to later-stage (Series C and beyond) investments, indicating that personalized therapeutics technology has matured and commercialization potential has increased. Additionally, participation from institutional investors such as sovereign wealth funds and pension funds is expanding. Korea Investment Corporation (KIC) committed $500 million to a personalized therapeutics fund in 2025, while Japan’s GPIF plans to invest $1.2 billion in the sector.
Technological Innovation and Commercialization Status
The most notable advancement in personalized therapeutics technology in 2026 is the commercialization of ‘real-time biomarker monitoring’ systems. The wearable biosensor developed by the Palo Alto, California-based startup ‘Precision BioSensors’ can monitor drug concentrations, immune response indicators, and tumor markers in real-time. This technology allows for the automatic adjustment of therapeutic dosages based on a patient’s real-time physiological responses and can predict and prevent side effects in advance. Clinical trials showed that patients using this system experienced a 56% improvement in treatment efficacy and a 48% reduction in side effects compared to traditional methods. The system is currently under review by the U.S. FDA and the European EMA, with commercialization expected in the latter half of 2026.
In the field of gene editing technology, the accuracy of ‘Prime Editing’ and ‘Base Editing’ has significantly improved. Next-generation editing tools that address the off-target effects of traditional CRISPR-Cas9 technology have been commercialized, greatly enhancing the safety of gene therapies. The ‘Ultra-Precise CRISPR’ system developed by the ‘Innovative Genomics Institute’ in Berkeley, California, achieves a target accuracy of 99.97%, reducing unwanted genetic changes to below 0.03%. A sickle cell disease therapy using this technology showed symptom improvement in 100% of patients in Phase 1 clinical trials, with no severe side effects reported. Additionally, gene editing costs have been significantly reduced, with the cost per patient dropping from $500,000 in 2024 to $180,000 in 2026, a 64% decrease.
Advancements in AI and machine learning are also bringing innovation to the development of personalized therapeutics. ‘DeepMind’, based in London, UK, has developed the ‘AlphaFold 3’ system, which boasts a protein structure prediction accuracy of 95.2% and an 87.4% accuracy in predicting drug-target interactions. This technology allows for the preemptive prediction of drug responses based on a patient’s genetic variations, reducing the design time for personalized therapeutics from six months to two weeks. ‘Adaptive Biotechnologies’, headquartered in Seattle, USA, has developed technology to accurately identify individual immune profiles through T-cell receptor repertoire analysis, enhancing the efficacy of CAR-T therapies by 78%. The company’s ‘immunoSEQ’ platform is currently used by 450 medical institutions worldwide and recorded $472 million in revenue in 2025.
In terms of manufacturing technology, ‘modular bio-manufacturing’ systems are gaining attention. ‘Celonic’, based in Munich, Germany, has developed a mobile bio-manufacturing facility that, despite its container size, can produce personalized therapeutics for 1,000 patients annually. These facilities can be installed near hospitals to manufacture therapeutics on demand, reducing logistics costs by 73% compared to centralized production. Additionally, the automation rate of the manufacturing process is 94%, significantly lowering labor costs. Currently, these facilities are being piloted in 15 hospitals across Europe, with plans to expand to North America and Asia in 2026. Samsung Biologics in Korea is also developing a similar ‘smart bio-factory’ concept, aiming for commercialization by 2027.
The future outlook for the personalized therapeutics market is highly positive. According to the latest report by global consulting firm McKinsey, the market is expected to grow at an average annual rate of 23.7%, reaching $240 billion by 2030. The Asia-Pacific region is projected to have the highest growth rate at 31.2%, with Korea expected to become the second-largest market in the region after Japan. However, challenges remain, particularly the high cost of treatment, with personalized therapeutics currently averaging 3-5 times the cost of traditional therapies. Governments and insurance companies are exploring reimbursement options, and the Korean government plans to implement a selective reimbursement system for personalized therapeutics starting in 2026.
Changes in the regulatory environment are also significantly impacting market development. The FDA released ‘Personalized Therapeutics Guidelines’ in December 2025, aiming to standardize the approval process and shorten approval timelines. For rare disease treatments, ‘adaptive clinical trial designs’ are permitted to ensure statistical significance even with small patient numbers. The European EMA is preparing similar guidelines, expected to be announced in the first half of 2026. These regulatory improvements are anticipated to facilitate more active market entry for personalized therapeutics. Investor interest continues to grow, with long-term investors such as pension funds and insurance companies expanding their investments in this sector. This indicates that personalized therapeutics have become a key driver of paradigm shifts across the healthcare industry, beyond mere technological innovation.
*This article is intended for informational purposes only and is not a solicitation for investment or a recommendation of specific stocks. Investment decisions should be made based on individual judgment and responsibility.*
